John Reed
Amministratore Delegato presso SYNTHORX, INC.
Patrimonio netto: 2 M $ in data 30/04/2024
Profilo
John C. Reed ha fondato Idun Pharmaceuticals, Inc. e Apoptos, Inc. Attualmente, il Dr. Reed è EVP & Global Head-Research & Development di Sanofi e presidente di Principia Biopharma, Inc. e presidente e direttore di Synthorx, Inc. (entrambe sono filiali di Sanofi). È anche nel consiglio di BIOCOM. Nella sua carriera passata John C. Reed ha occupato la posizione di Head-Roche Pharma Research & Early Development alla Roche Holding AG, Presidente, Amministratore Delegato e Professore al Sanford Burnham Prebys Medical Discovery Institute, Assistente Direttore all'Università della Pennsylvania, Membro associato all'Università della California San Diego e Membro associato al Whitaker Institute of Biomedical Engineering. Ha conseguito una laurea presso l'Università della Virginia e un dottorato presso la Perelman School of Medicine.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
JOHNSON & JOHNSON
0.00% | 01/05/2024 | 11 577 ( 0.00% ) | 2 M $ | 30/04/2024 |
Posizioni attive di John Reed
Società | Posizione | Inizio |
---|---|---|
SYNTHORX, INC. | Amministratore Delegato | - |
PRINCIPIA BIOPHARMA INC. | Presidente | - |
JOHNSON & JOHNSON | Corporate Officer/Principal | - |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Direttore/Membro del Consiglio | 24/06/2011 |
Precedenti posizioni note di John Reed
Società | Posizione | Fine |
---|---|---|
SANOFI | Direttore Tecnico/Scientifico/R&S | 13/02/2023 |
ROCHE HOLDING AG | Corporate Officer/Principal | 02/04/2018 |
CLOVIS ONCOLOGY, INC. | Direttore/Membro del Consiglio | 14/02/2013 |
IONIS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 12/02/2013 |
Whitaker Institute of Biomedical Engineering | Corporate Officer/Principal | 01/01/2013 |
Formazione di John Reed
University of Virginia | Undergraduate Degree |
Perelman School of Medicine | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 4 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
ROCHE HOLDING AG | Health Technology |
SANOFI | Health Technology |
JOHNSON & JOHNSON | Health Technology |
Aziende private | 11 |
---|---|
Stratagene Corp.
Stratagene Corp. Medical SpecialtiesHealth Technology Stratagene Corp. researches, develops and markets diagnostic products and technologies for life science research. The company's products are used in the research of amplification, cell biology, cloning, microarrays, nucleic acid analysis, protein function and analysis, and quantitative PCR. Its clients include the industrial and government research sectors. The firm sells its products in more than 60 countries. Stratagene was founded in 1984 and is located in La Jolla, CA. | Health Technology |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Health Services |
Repros Therapeutics, Inc.
Repros Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Repros Therapeutics, Inc. is a development stage biopharmaceutical company, which focuses on the development of drugs to treat hormonal and reproductive systems disorders. Its products include Enclomiphene and Proellex. The company was founded on August 20, 1987 and is headquartered in The Woodlands, TX. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
Idun Pharmaceuticals, Inc.
Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Health Technology |
Apoptos, Inc.
Apoptos, Inc. Pharmaceuticals: MajorHealth Technology Apoptos, Inc. discovers and develops small molecule anticancer drugs. The company focuses in drug therapies that directly induce tumor cell apoptosis. It was founded in 2007 and is headquartered in San Diego, CA | Health Technology |
Synthorx, Inc.
Synthorx, Inc. BiotechnologyHealth Technology Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA. | Health Technology |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- John Reed